Comments
Mankind Pharma on Wednesday said it has joined hands with BDR Pharmaceuticals to launch oral anti Covid-19 pill Molulife (Molnupiravir) in the country.
The tie-up is a licensing arrangement where production is by BDR Pharma and marketing, selling, promotion, distribution is by Mankind Pharma, the company said in a statement.
On Tuesday, the Drugs Controller General of India (DCGI) granted permission for restricted use of antiviral medication Molnupiravir under emergency situation for treatment of Covid-19 in adult patients who have a high risk of progression of the disease.
“This launch further enhances the Covid-19 treatment portfolio in BDR’s product basket with the addition of generic Molnupiravir. We are pleased to collaborate with Mankind Pharma to take one step forward in fighting the virus,” BDR Pharma Director – Business Development Raheel Shah stated.
Mankind Pharma Senior President (Sales & Marketing) Sanjay Koul noted that a pill for Covid-19 is bound to go miles in strengthening defense against the Covid-19 battle.
Mankind with its motto ‘serving life’- will make Molulife available in every nook and corner of the country, he added.
“The company focuses on providing a range of medicines for the management and treatment of Covid-19 in India,” Koul said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.